Cancer Drug Advances Take Center Stage at ASCO 2026
New cancer drug data presented at the 2026 American Society of Clinical Oncology meeting highlighted a wave of experimental treatments showing encouraging results in hard-to-treat cancers, including pancreatic, lung, and solid tumors resistant to prior immunotherapy. While the findings point to meaningful progress, most of the therapies are still in clinical development and have not yet become standard treatment.
One of the standout updates came from Greywolf Therapeutics’ GRWD5769, an oral ERAP1 inhibitor designed to make tumor cells more visible to the immune system. In early-stage trial data, the drug combined with cemiplimab showed clinical activity across six solid tumor types, with some patients experiencing durable tumor shrinkage and disease control after failing previous therapies.
Another major development involved daraxonrasib, an oral KRAS-targeted therapy being studied in metastatic pancreatic cancer. Trial results presented at ASCO showed improved survival compared with chemotherapy, adding to growing interest in targeted approaches for one of the deadliest forms of cancer.
Ivonescimab also drew attention after phase III data suggested a survival benefit in advanced squamous non-small cell lung cancer when paired with chemotherapy. The study reinforced the growing momentum behind bispecific and combination therapies aimed at improving outcomes in lung cancer.
Researchers also discussed ozekibart, an investigational therapy showing early signs of activity in bowel and other cancers. However, experts caution that the findings remain preliminary and need additional study before any firm conclusions can be drawn.
Why it matters
The latest ASCO findings reflect a broader shift in oncology toward more precise, targeted treatments that may help patients who no longer respond to standard immunotherapy or chemotherapy. For now, the results are promising signs of progress rather than immediate practice-changing breakthroughs.
Sources
- The Guardian, ASCO 2026 cancer coverage, June 2026
- Greywolf Therapeutics / ASCO trial data on GRWD5769
- ASCO 2026 reporting on daraxonrasib and ivonescimab
*Written with the help of AI. Let us know if you have concerns or questions.
